News & Updates

Show Multimedia Only

COVID-19 vaccine for kids: How young can we go?

02 Apr 2022 by

While the mRNA vaccines currently available on the market have gained regulatory nods* for use in children aged 5 or 6 years old**, Moderna’s mRNA-1273 vaccine is setting a “new low” by showing that two 25 μg doses of the vaccine induce a robust immune response in infants/children as young as 6 months to <6 years of age, according to the latest data from the KidCOVE study.

02 Apr 2022

Addressing the unmet needs and challenges in managing older AF patients

01 Apr 2022 by

A key focus in the management of atrial fibrillation (AF) in older patients is stroke prevention through oral anticoagulation. However, a significant proportion of older AF patients remain undercoagulated due to the perceived bleeding risk of oral anticoagulants (OACs). Dr Tan Vern Hsen, Senior Consultant, Department of Cardiology, Changi General Hospital, Singapore, and Dr Barbara Helen Rosario, Senior Consultant, Department of Geriatric Medicine, Changi General Hospital, Singapore, shared their respective insights into managing older AF patients for an integrated approach.

01 Apr 2022

Optimal protection in geriatric patients with atrial fibrillation: An expert’s perspective

01 Apr 2022 by

Geriatric patients with atrial fibrillation (AF) are at increased risk of blood clots that can lodge in the brain and cause fatal strokes. At a recent webinar, Professor Olivier Hanon, Head of Geriatrics Department in Broca Hospital, Paris, France, shared insights on how to optimally protect geriatric patients with AF, with a special focus on direct oral anticoagulants (DOACs), particularly rivaroxaban, for stroke prevention in AF.

01 Apr 2022

$Tislelizumab produces long-term benefits in relapsed, refractory classical Hodgkin lymphoma$

Tislelizumab produces long-term benefits in relapsed, refractory classical Hodgkin lymphoma

01 Apr 2022

Treatment with the antiprogrammed cell death protein 1 (anti–PD-1) monoclonal antibody tislelizumab yields high response rates in relapsed or refractory classical Hodgkin's lymphoma, with a similar toxicity profile as other anti–PD-1 therapies, as shown in the extended results of a phase II trial.

01 Apr 2022

Role of apixaban in VTE management: Who, when, and how

31 Mar 2022 by

Venous thromboembolism (VTE) is associated with an increased risk of morbidity and mortality. Given the challenges posed by conventional therapies used for the treatment of VTE, Dr Lim Xiu Qi Cheryl, Associate Consultant from the Department of Haematology-Oncology at National University Cancer Institute, Singapore (NCIS), shares her insights on the role of apixaban (Eliquis, Pfizer), an oral factor Xa inhibitor, in the treatment of acute VTE and prevention of recurrent VTE.

31 Mar 2022

Empagliflozin benefits similar between MRA users, nonusers

31 Mar 2022

In patients with heart failure (HF) and preserved ejection fraction, treatment with empagliflozin delivers comparable benefits in reducing first hospitalization for HF or cardiovascular death (primary outcome) between users and nonusers of mineralocorticoid receptor antagonists (MRA), reports a study.

31 Mar 2022

Benralizumab reduces asthma exacerbation rates in real-world setting

31 Mar 2022 by

Treatment with benralizumab significantly reduces exacerbation rates in patients with asthma in a real-world setting, according to the ZEPHYR 2 study presented at AAAAI 2022.

31 Mar 2022

Tezepelumab cuts asthma attacks in patients with severe asthma across seasons

30 Mar 2022 by

Not only does tezepelumab reduce asthma symptomatic days, it prevents asthma exacerbations across all seasons in adolescents and adults with severe, uncontrolled asthma, according to the prespecified exploratory analyses of the NAVIGATOR trial presented at AAAAI 2022.

30 Mar 2022